CANCER AND LEUKEMIA GROUP B

加州大学圣地亚哥分校列出的调查人员 医学和附属机构计划继续活跃， 癌症和白血病B组(CALGB)的多学科成员。我们 目标是(1)增加集团研究的应计费用(预计总数为 110-125名患者/年)，(2)参与指导知识分子 集团的生产力(通过激励更多的基础研究组成部分来实现 临床试验，设计和主持方案，介绍试点 对集团验证和扩展的观察)，3)增加参与 小组行政活动(接受任命为委员会成员 主席、核心委员会成员、礼宾主席)(4)提供直接服务 对组(通过维护活动的单元格表面标记引用 技术素质超高、科学过硬的实验室 成熟，是扩张的制度基础 CALGB的微型计算机应用)，以及(5)作为 CCOP活动的临床资源和多学科研究基地 (这将进一步增加CALGB踪迹的应计费用)。续 参加CALGB将显著提高 在整个圣地亚哥地区提供肿瘤学护理，并作为 教职员工、研究员、管家和学生的重要教育工具 在加州大学圣迭戈分校及其附属参与者。 更多的工作人员和受训人员参加CALGB活动提供了 扩大患者基础(海军地区圣地亚哥退伍军人医疗中心 私人圣地亚哥肿瘤学社区的医疗中心和我们的 CCOP在内华达州拉斯维加斯的分支机构)和所有符合条件的患者进入 适当的CALGB试验(通过增加数据促进 管理/秘书事务)应允许实现应计项目 目标。医生更多地参加CALGB全国会议 UCSD的工作人员应该导致新的委员会任命，礼仪 发展机会，并从我们的 机构。加州大学圣迭戈分校癌症中心的基础科学资源将是 可用于为新试验提供实验室研究组件。这个 细胞表面标记参考实验室可以将其贡献扩大为 进一步的群组协议被开发出来，它利用其复杂的 能力。这一全面参与有望使加州大学圣迭戈分校 和CALGB为癌症的治疗做出有意义的贡献。

The listed investigators at the University of California San Diego School of Medicine and adjunct institutions plan to continue active, multidisciplinary membership in Cancer and Leukemia Group B (CALGB). We aim to (1) increase accrual to Group studies (to a projected total of 110-125 patients/year), (2) participate in directing intellectual productivity of the Group (by stimulating more basic research components to clinical trials, designing and chairing protocol, presenting pilot observation for Group validation and expansion), 3) increase involvement in Group administrative activities (by accepting appointments as committee chairs, core committee members, protocol chairs) (4) provide direct service to the Group (by maintaining an active Cell Surface Marker Reference Laboratory of exceptionally high technical quality and scientific sophistication and serving as the Institutional base for expanding microcomputer applications for CALGB as a whole), and (5) serve as a clinical resource and multidisciplinary research base for CCOP activities (which will further enhance accrual to CALGB trails). Continued participation in CALGB will measurably improve the overall quality of Oncology care delivered in the entire San Diego area and serve as an important educational vehicle for Faculty, Fellows, Housestaff and students at UCSD and affiliated participants. Increased staff and trainee participation in CALGB activities offer an expanded patient base (at San Diego VA Medical Center, Naval Regional Medical Center, in the private San Diego Oncology Community, and at our CCOP affiliate in Las Vegas, Nevada) and entry of all eligible patients on appropriate CALGB trials (facilitated by increased data management/secretarial services) should permit achievement of accrual goals. Increased participation at CALGB national meetings by physicians and staff from UCSD should lead to new committee appointments, protocol development opportunities, and broadened intellectual input from our institution. The basic science resources of the UCSD Cancer Center will be available to provide laboratory research components for new trials. The Cell Surface Marker Reference Laboratory can expand its contributions as further Group protocols are developed which utilize its sophisticated capabilities. This overall participation will hopefully allow both UCSD and CALGB to make meaningful contributions toward the cure of cancer.